Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS)
Authors:
- Burgess B. FreemanBFBurgess B. Freeman
- Clinton F. StewartCSClinton F. Stewart
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 831 (1-2) , 169-175
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor LapatinibThe Oncologist, 2004
- Increasing throughput of parallel on‐line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug developmentRapid Communications in Mass Spectrometry, 2004
- Ion Suppression in Mass SpectrometryClinical Chemistry, 2003
- Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene, 2002
- The type III epidermal growth factor receptor mutationAnnals of Oncology, 2001
- Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2Bioorganic & Medicinal Chemistry Letters, 2001
- Mechanistic investigation of ionization suppression in electrospray ionizationJournal of the American Society for Mass Spectrometry, 2000
- Effect of stationary phase structure on retention and selectivity in reversed-phase liquid chromatographyJournal of Chromatography A, 1982